Department of Health
and Human Services (HHS)
and Human Services (HHS)
RESCINDED
PAR-20-100 - Genomic Community Resources (U24)
RFA-HG-20-014 - Novel Synthetic Nucleic Acid Technology Development (R01) (Clinical Trial not Allowed)
RFA-HG-20-015 - Novel Synthetic Nucleic Acid Technology Development (R21) (Clinical Trial not Allowed)
RFA-HG-20-016 - Novel Synthetic Nucleic Acid Technology Development (R43/R44) (Clinical Trial not Allowed)
RFA-HG-20-019 - NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed)
PAR-19-204 - Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)
RFA-HG-18-001 - Novel Nucleic Acid Sequencing Technology Development (R01 Clinical Trial Not Allowed)
RFA-HG-18-002 - Novel Nucleic Acid Sequencing Technology Development (R21 Clinical Trial Not Allowed)
RFA-HG-18-003 - Novel Nucleic Acid Sequencing Technology Development (R43/R44 Clinical Trial Not Allowed)
RFA-HG-20-001 -Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry-Study Sites (U01 Clinical Trial Not Allowed)
RFA-HG-20-002 - Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry-Coordinating Center (U01 Clinical Trial Not Allowed)
National Human Genome Research Institute (NHGRI)
Late applications will be accepted by 5:00 PM local time up to two weeks after the application due date for the FOAs listed below. Institutions do not need to request advance permission. While a cover letter citing this Notice may be provided, it is not required to take advantage of this flexibility. NIH’s late application submission policy for institutions closed due to the effects of COVID-19 (NOT-OD-20-082) still applies to these FOAs for institutions that are not able to submit within the two-week window. However, note that late applications submitted per NOT-OD-20-082 are considered on a case-by-case basis.
| Title of FOA | FOA number | Applicable Application Due Date(s) New | Applicable/Application Receipt Date, Renewal/Resubmission/Revision (as allowed in the FOA). |
| Genomic Community Resources (U24) | PAR-20-100 | 8-Jun-20 | 8-Jun-20 |
| Novel Synthetic Nucleic Acid Technology Development (R01 Clinical Trial not allowed) | RFA-HG-20-014 | 8-Jul-20 | 8-Jul-20 |
| Novel Synthetic Nucleic Acid Technology Development (R21) (Clinical Trial not allowed) | RFA-HG-20-015 | 8-Jul-20 | 8-Jul-20 |
| Novel Synthetic Nucleic Acid Technology Development (R43/R44) (Clinical Trial Not Allowed) | RFA-HG-20-016 | 8-Jul-20 | 8-Jul-20 |
| NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed) | RFA-HG-20-019 | 8-Jul-20 | 8-Jul-20 |
| Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional) | PAR-19-204 | 1-Jun-20 | 1-Jun-20 |
| Novel Nucleic Acid Sequencing Technology Development (R01 Clinical Trial Not Allowed) | RFA-HG-18-001 | 10-Jul-20 | 10-Jul-20 |
| Novel Nucleic Acid Sequencing Technology Development (R21 Clinical Trial Not Allowed) | RFA-HG-18-002 | 10-Jul-20 | 10-Jul-20 |
| Novel Nucleic Acid Sequencing Technology Development (R43/R44 Clinical Trial Not Allowed) | RFA-HG-18-003 | 10-Jul-20 | 10-Jul-20 |
| Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry – Study Sites (U01 Clinical Trial Not Allowed) | RFA-HG-20-001 | 7-Jul-20 | 7-Jul-20 |
| Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry – Coordinating Center (U01 Clinical Trial Not Allowed) | RFA-HG-20-002 | 7-Jul-20 | 7-Jul-20 |
All other FOAs will follow the standard NIH late application policies, including considerations related to the emergency declaration for COVID-19 (NOT-OD-20-082).
Bettie J. Graham, Ph.D.
National Human Genome Research Institute (NHGRI)
Telephone: 301-496-7531
Email: [email protected]